Cover Image
市場調查報告書

脊髓性小腦萎縮症:開發中產品分析

Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 245961
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
脊髓性小腦萎縮症:開發中產品分析 Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 55 Pages
簡介

脊髓性小腦萎縮症(SCA)是遺傳性疾病的一種,作用於腦跟脊髓,並引起漸進式的協調障礙(運動失調)。常見的症狀有運動失調,步行不穩,口吃,語言變化,吞嚥障礙等。

本報告提供全球各國治療脊髓性小腦萎縮症所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查資訊。

簡介

  • 分析範圍

脊髓性小腦萎縮症概要

治療藥的開發

  • 脊髓性小腦萎縮症轉動開發中產品:概要
  • 脊髓性小腦萎縮症轉動開發中產品:比較分析

各企業開發中的脊髓性小腦萎縮症治療藥

大學/研究機關研究中的脊髓性小腦萎縮症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

脊髓性小腦萎縮症治療藥:開發中的產品一覽(各企業)

脊髓性小腦萎縮症治療藥:研究中的產品一覽(各大學/研究機關)

脊髓性小腦萎縮症開發治療藥的企業

  • Baxalta Incorporated
  • Bioblast Pharma Ltd.
  • Kissei藥品工業
  • Vybion, Inc

脊髓性小腦萎縮症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

脊髓性小腦萎縮症治療藥:最新的藥物簡介

脊髓性小腦萎縮症治療藥:暫停開發的產品

脊髓性小腦萎縮症治療藥:產品開發的里程碑

  • 最新消息及新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8119IDB

Summary

Global Markets Direct's, 'Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2016', provides an overview of the Spinocerebellar Ataxia (SCA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA)
  • The report reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Spinocerebellar Ataxia (SCA) therapeutics and enlists all their major and minor projects
  • The report assesses Spinocerebellar Ataxia (SCA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Spinocerebellar Ataxia (SCA)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Spinocerebellar Ataxia (SCA) Overview
  • Therapeutics Development
    • Pipeline Products for Spinocerebellar Ataxia (SCA) - Overview
    • Pipeline Products for Spinocerebellar Ataxia (SCA) - Comparative Analysis
  • Spinocerebellar Ataxia (SCA) - Therapeutics under Development by Companies
  • Spinocerebellar Ataxia (SCA) - Therapeutics under Investigation by Universities/Institutes
  • Spinocerebellar Ataxia (SCA) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Spinocerebellar Ataxia (SCA) - Products under Development by Companies
  • Spinocerebellar Ataxia (SCA) - Products under Investigation by Universities/Institutes
  • Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
    • Baxalta Incorporated
    • Bioblast Pharma Ltd.
    • Kissei Pharmaceutical Co., Ltd.
    • Vybion, Inc.
  • Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Ataxin-7 for Spinocerebellar Ataxia Type 7 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-41 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • riluzole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Gene Therapy for Machado-Joseph Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rovatirelin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trehalose - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Spinocerebellar Ataxia (SCA) - Recent Pipeline Updates
  • Spinocerebellar Ataxia (SCA) - Dormant Projects
  • Spinocerebellar Ataxia (SCA) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2016: Portage Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
      • Sep 14, 2015: BioBlast Granted Patent From USPTO for Cabaletta for the Treatment of Spinocerebellar Ataxia
      • Jun 29, 2015: BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Spinocerebellar Ataxia
      • Mar 30, 2015: BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of Its Cabaletta Platform in Spinocerebellar Ataxia Type 3
      • Nov 19, 2014: Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2016
  • Number of Products under Development for Spinocerebellar Ataxia (SCA) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Spinocerebellar Ataxia (SCA) - Pipeline by Baxalta Incorporated, H1 2016
  • Spinocerebellar Ataxia (SCA) - Pipeline by Bioblast Pharma Ltd., H1 2016
  • Spinocerebellar Ataxia (SCA) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Spinocerebellar Ataxia (SCA) - Pipeline by Vybion, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Spinocerebellar Ataxia (SCA) Therapeutics - Recent Pipeline Updates, H1 2016
  • Spinocerebellar Ataxia (SCA) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2016
  • Number of Products under Development for Spinocerebellar Ataxia (SCA) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top